potency and developability optimization

ArrePath is a drug discovery company that uses target-specific AI/ML workflows to discover oral small molecules. It begins with a desired candidate profile, then deploys AI/ML workflows to evaluate novel chemistry while optimizing potency and developability in parallel. The company validated its platform by discovering six new antibacterial classes with six new mechanisms of action in four years, and is now applying the platform to validated targets where oral-small-molecule options are limited. It is based in Princeton, NJ.

Read more

novel chemistry explorationoral bioavailability optimizationoral small-molecule discoverytarget-specific AI/ML workflows